Onesource Specialty Pharma Ltd

Revenue from operations increased 37% year-on-year (YoY) to Rs 449.02 crore in Q1 FY27 from Rs 3,273 crore in Q1 FY26, driven by the commercial launch of semaglutide, new master service agreement (MSA) contracts, and customer wins across its business segments. The company reported a profit before exceptional items and tax of Rs 24.59 crore during the quarter, compared with a loss before exceptional items and tax of Rs 1.52 crore in the year-ago period. During the quarter, the company recorded an exceptional loss of Rs 4.30 crore on account of legal charges related to legacy litigation involving employees of a subsidiary. EBITDA stood at Rs 123.3 crore, registering the growth of 39% YoY. EBITDA margin improved to 27.5% in Q1 FY27 as against 27% in Q1 FY26. Looking ahead, the company reiterated its FY28 guidance, targeting $400 million in organic revenue and an EBITDA margin of 40%, reflecting confidence in its long-term growth trajectory. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said, 'We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.' OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). Powered by Capital Market - Live

Net profit of OneSource Specialty Pharma reported to Rs 25.00 crore in the quarter ended June 2026 as against net loss of Rs 0.19 crore during the previous quarter ended June 2025. Sales rose 37.20% to Rs 449.02 crore in the quarter ended June 2026 as against Rs 327.27 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales449.02327.27 37 OPM %27.4727.04 - PBDT96.3466.27 45 PBT24.59-1.53 LP NP25.00-0.19 LP Powered by Capital Market - Live

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2026.

OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics' facility in Bangalore. The collaboration brings together Formycon's Biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.

OneSource Specialty Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from 22 June 2026 to 30 June 2026. The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.

Net profit of OneSource Specialty Pharma declined 95.33% to Rs 4.60 crore in the quarter ended March 2026 as against Rs 98.50 crore during the previous quarter ended March 2025. Sales rose 0.53% to Rs 428.22 crore in the quarter ended March 2026 as against Rs 425.95 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales428.22425.95 1 1421.591444.85 -2 OPM %21.4742.85 -21.4032.29 - PBDT71.50151.99 -53 197.06317.67 -38 PBT-0.3283.50 PL -82.0343.78 PL NP4.6098.50 -95 -73.80-17.97 -311 Powered by Capital Market - Live

OneSource Specialty Pharma has allotted 3,150 equity shares under ESOP on 13 May 2026. With this allotment, the paid up equity share capital has increased to 114,645,801 equity shares of Re. 1/- each.

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 13 May 2026.

OneSource Specialty Pharma announced that its partner Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic'. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: 'We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic'. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities.'

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic' (Semaglutide Injection). OneSource is the contract development and manufacturing organization (CDMO) partner for this product. This milestone highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from OneSource's US-FDA approved flagship site in Bangalore. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma, speaking on the development, said: 'We are pleased to announce that our partner Orbicular, along with its front-end partner (the ANDA holder), has received tentative approval for a generic version of Ozempic' (Semaglutide Injection). This milestone reflects Orbicular's scientific expertise and OneSource's CDMO capabilities, supported by our US-FDA approved manufacturing site.'